As of Q4'25, Pfizer's latest revenue surprise percentage stands at 4.2%, while year-over-year revenue growth is at -1.2%. This marks a modest positive revenue surprise alongside a slight decline in annual revenue growth for the most recent quarter. From Q1'23 to Q4'25, the revenue surprise percentage has shown considerable volatility, peaking at 18.6% in Q3'24 and dipping into negative territory in Q1'25 (-1.5%). Year-over-year revenue growth experienced a significant downturn throughout 2023, reaching as low as -54.1% in Q2'23, but rebounded to positive territory in mid-2024, with the highest growth of 33.8% in Q3'24. However, this recovery was not sustained, as growth rates turned negative again in late 2025, indicating ongoing fluctuations and a lack of consistent upward momentum. The chart highlights a period of sharp contraction followed by a partial recovery and renewed softness in both revenue surprises and growth.